Recent Updates
Recently added Catalysts
DNTH Positive Sentiment

Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference

Tuesday, February 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dianthus Therapeutics, a clinical-stage biotechnology firm, will participate in the TD Cowen 46th Annual Health Care Conference in Boston. CEO Marino Garcia is scheduled for an analyst-led fireside chat on March 3, 2026, and will also hold one-on-one meetings with investors. This event highlights the company's commitment to advancing treatments for severe autoimmune diseases.
Price reaction · baseline $52.68 (2026-02-23 close) · hit pre-market · clean, no other DNTH news in the window
day 0 close
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dianthus Therapeutics is actively participating in a major healthcare conference.
  • The CEO will engage in a fireside chat, showcasing company transparency.
  • One-on-one meetings with investors indicate strong interest and potential support.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+165%
120-day peak, hindsight
Typical move
3.2%
average across 2 past catalysts
Cash runway
~54 mo
Minimal dilution risk
Lead asset
MGTA-456
Phase 2 · Inherited Metabolic Disorders (IMD)

Full Press Release Details

NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46thAnnual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors.
A webcast of this presentation may be accessed under “News and Events” in theInvestorssection of the Dianthus Therapeuticswebsite.
About Dianthus TherapeuticsDianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visitwww.dianthustx.comand follow us onLinkedIn.

ContactJennifer Davis RuffDianthus Therapeuticsjdavisruff@dianthustx.com

Frequently Asked Questions

When will Dianthus participate in the TD Cowen Conference?

Dianthus Therapeutics will participate on March 3, 2026.

Who will represent Dianthus at the conference?

CEO Marino Garcia will represent Dianthus Therapeutics.

What type of event will Marino Garcia participate in?

He will engage in an analyst-led fireside chat.

Where can I access the conference webcast?

The webcast will be available under 'News and Events' on their website.

ShareAdd on Google
Tags: DNTH Viatris Investor Conferences Healthcare Dianthus Therapeutics healthcare conference autoimmune diseases Marino Garcia
Last updated: Feb 24, 2026

Biotech snapshot

Cash runway
$887M liquidity · $16M/mo burn
~54 mo
Minimal dilution risk
Lead asset
MGTA-456Phase 2
Inherited Metabolic Disorders (IMD) →

Catalyst track record

+165%
best trade around DNTH's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DNTH.

See every catalyst's timing & PoA →